TYROSINE KINASE INHIBITORS .5. SYNTHESIS AND STRUCTURE-ACTIVITY-RELATIONSHIPS FOR 4-[(PHENYLMETHYL)AMINO]-QUINAZOLINES AND 4-(PHENYLAMINO)QUINAZOLINES AS POTENT ADENOSINE 5'-TRIPHOSPHATE BINDING-SITE INHIBITORS OF THE TYROSINE KINASE DOMAIN OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR

被引:260
作者
REWCASTLE, GW
DENNY, WA
BRIDGES, AJ
ZHOU, HR
CODY, DR
MCMICHAEL, A
FRY, DW
机构
[1] UNIV AUCKLAND,SCH MED,CANC RES LAB,AUCKLAND,NEW ZEALAND
[2] PARKE DAVIS PHARMACEUT RES,ANN ARBOR,MI 48106
关键词
D O I
10.1021/jm00018a008
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of 4-substituted quinazolines and related compounds have been prepared and evaluated for their ability to inhibit the tyrosine kinase activity of the epidermal growth factor receptor on a phospholipase C-gamma 1-derived substrate. The results show a narrow structure-activity relationship (SAR) for the basic ring system, with quinazoline being the preferred chromophore and benzylamino and anilino the preferred side chains. In the 4-anilino series, substitution on the 3-position of the phenyl ring with small lipophilic electron-withdrawing groups provided analogues with enhanced potency. Two series of compounds [4-(phenylmethyl)amino and 4-(3-bromophenyl)amino] were studied to determine SARs for quinazoline substituents. In the more active 4-(3-bromophenyl)amino series, electron-donating groups (NH2, OMe) at the 6- or 7-position increased activity, in a pattern consistent with a requirement for high electron density in the vicinity of the 8-position of the quinazoline ring. The 6,7-dimethoxy derivatives were the most effective in both series, with the 4-(3-bromophenyl)amino derivative (3) having an IC50 Of 0.029 nM, making it by far the most potent reported inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor enzyme.
引用
收藏
页码:3482 / 3487
页数:6
相关论文
共 36 条
  • [1] ATKINSON CM, 1956, J CHEM SOC, P1081
  • [2] AN ANTIMALARIAL ALKALOID FROM HYDRANGEA .14. SYNTHESIS OF 5-MONOSUBSTITUTED, 6-MONOSUBSTITUTED, 7-MONOSUBSTITUTED, AND 8-MONOSUBSTITUTED DERIVATIVES
    BAKER, BR
    SCHAUB, RE
    JOSEPH, JP
    MCEVOY, FJ
    WILLIAMS, JH
    [J]. JOURNAL OF ORGANIC CHEMISTRY, 1952, 17 (01) : 141 - 148
  • [3] Barker A., 1993, Patent, Patent No. [EP0566226, 0566226]
  • [4] BARKER AJ, 1992, Patent No. [520722, 0520722]
  • [5] BURKE T R JR, 1992, Drugs of the Future, V17, P119
  • [6] BICYCLIC COMPOUNDS AS RING-CONSTRAINED INHIBITORS OF PROTEIN-TYROSINE KINASE-P56LCK
    BURKE, TR
    LIM, B
    MARQUEZ, VE
    LI, ZH
    BOLEN, JB
    STEFANOVA, I
    HORAK, ID
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (04) : 425 - 432
  • [7] ARYLAMIDES OF HYDROXYLATED ISOQUINOLINES AS PROTEIN-TYROSINE KINASE INHIBITORS
    BURKE, TR
    FORD, H
    OSHEROV, N
    LEVITZKI, A
    STEFANOVA, I
    HORAK, ID
    MARQUEZ, VE
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1992, 2 (12) : 1771 - 1774
  • [8] PROTEIN-TYROSINE KINASE INHIBITION - MECHANISM-BASED DISCOVERY OF ANTITUMOR AGENTS
    CHANG, CJ
    GEAHLEN, RL
    [J]. JOURNAL OF NATURAL PRODUCTS, 1992, 55 (11): : 1529 - 1560
  • [9] Dobrusin EM, 1992, ANNU REP MED CHEM, V27, P169
  • [10] 5,7-DIMETHOXY-3-(4-PYRIDINYL)QUINOLINE IS A POTENT AND SELECTIVE INHIBITOR OF HUMAN VASCULAR BETA-TYPE PLATELET-DERIVED GROWTH-FACTOR RECEPTOR TYROSINE KINASE
    DOLLE, RE
    DUNN, JA
    BOBKO, M
    SINGH, B
    KUSTER, JE
    BAIZMAN, E
    HARRIS, AL
    SAWUTZ, DG
    MILLER, D
    WANG, S
    FALTYNEK, CR
    XIE, W
    SARUP, J
    BODE, DC
    PAGANI, ED
    SILVER, PJ
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (17) : 2627 - 2629